In a symposium beginning Sunday at 4:30 p.m. in Ballroom 20A-C, Vanita R. Aroda, MD, will share results from two trials, OASIS 1 and PIONEER PLUS, and discuss the effectiveness of higher dose semaglutide in treating patients with type 2 diabetes as well as patients with obesity without type 2 diabetes. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Up next: Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trials
